Drug Trial Radar · NCT07589387
Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,800
Planned (sponsor's estimate)
Start
Feb 14, 2026
Primary completion
Apr 30, 2029
Study completion Jan 31, 2030
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI); University of Abuja Teaching Hospital
- First posted
- May 15, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the second phase of the Hypertension Treatment in Nigeria (HTN 2.0) Program is to build upon the success of the first phase of the HTN Program (2020-2023), which implemented the WHO HEARTS package across 60 primary healthcare centers (PHCs) in the Federal Capital Territory (FCT). This program demonstrated significant improvements in hypertension treatment and control. The focus of aim 3 will be evaluating diabetes management through the implementation of the HEARTS-D bundle in 10 PHCs across the FCT that previously participated in the initial HTN Program.
Conditions
- Diabete Mellitus
Interventions
Implementation of program based on WHO HEARTS-D guidelinesOther
This study uses an interrupted time series design to compare diabetes screening, diagnosis, treatment, and control across a 12-month pre-implementation period and a 24-month implementation period in 10 primary healthcare centers in Nigeria's Federal Capital Territory. Sites previously demonstrated capacity to deliver hypertension care and will continue hypertension services while expanding to diabetes care through the HEARTS diabetes module (HEARTS-D). Pre-implementation includes registry setup and provision of glucometers without diabetes treatment training. Implementation includes HEARTS-D training, supply provision, expansion of the drug revolving fund to diabetes medicines, and quarterly supportive supervision.
MetforminDrug
Description: Oral biguanide used as first-line glucose-lowering therapy within the HEARTS-D stepped-care protocol. Dosing per protocol: 500 mg once daily (Step 1), 1000 mg once daily (Step 2), 1000 mg twice daily (Step 3 and Step 4). Supplied through the expanded drug revolving fund during the implementation period.
GlimepirideDrug
Oral sulfonylurea used as add-on therapy at Step 4 of the HEARTS-D stepped-care protocol when blood glucose remains uncontrolled on metformin. Starting dose 1 mg once daily, titrated by 1-2 mg to a maximum of 8 mg daily. Supplied through the expanded drug revolving fund during the implementation period.
Point-of-care blood glucose monitor (glucometer) and compatible test stripsDevice
Point-of-care capillary blood glucose monitor with compatible single-use test strips and lancets, used at participating primary health centers for diabetes screening, diagnosis, and monitoring per WHO HEARTS-D. Glucometers and test strips are provided to all sites during pre-implementation (registry setup) and replenished during implementation through the supply chain and drug revolving fund.
HEARTS-D training and quarterly supportive supervision for community health extension workers (CHEWs)Behavioral
Structured training of CHEWs on the HEARTS-D protocol covering diabetes screening, diagnosis, stepped-care treatment, follow-up, and referral, delivered at the start of the implementation period and reinforced by quarterly supportive supervision visits with audit-and-feedback throughout the 24-month implementation period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose of quarterly supportive supervision visits measured by the proportion of observed/expected visits during the implementation period.Time frame: 36 months
- Difference in 6-month rolling average of blood glucose control in patients with diabetes (random blood glucose ≤11.1 mmol/L while receiving treatment; or fasting plasma glucose/HbA1c within target, as available) per WHO HEARTS-D, pre- vs. implementationTime frame: 36 months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
New Township Abaji
Abaji, Nigeria · Recruiting
Gbagarape PHC
Abuja, Nigeria · Recruiting
Gidan Mangoro
Abuja, Nigeria · Recruiting
Pyakasa PHC
Abuja, Nigeria · Recruiting
Byazhin
Bwari, Nigeria · Recruiting
Gtc Gwagwalada
Gwagwalada, Nigeria · Recruiting
Old Kutunku
Gwagwalada, Nigeria · Recruiting
Kuje PHC
Kuje, Nigeria · Recruiting
Dabi Bako
Kwali, Nigeria · Recruiting
KAWLI
Kwali, Nigeria · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.